Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 0.73 |
| ▸ | TGFBR2 | P37173 | 13/20 | 0.73 |
| ▸ | BUB1 | O43683 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17840951 | 0.92 | TGFBR1 (0.76) | TGFBR1TGFBR2 | |
| SCHEMBL17840663 | 0.91 | TGFBR1 (0.73) | TGFBR1TGFBR2BUB1 | |
| SCHEMBL17881790 | 0.90 | TGFBR1 (0.70) | TGFBR1TGFBR2BUB1AAK1 | |
| SCHEMBL17840770 | 0.90 | TGFBR1 (0.72) | TGFBR1TGFBR2BUB1 | |
| SCHEMBL17863780 | 0.89 | TGFBR1 (0.69) | TGFBR1TGFBR2BUB1AAK1 | |
| SCHEMBL17840656 | 0.88 | TGFBR1 (0.79) | TGFBR1TGFBR2 | |
| SCHEMBL17840960 | 0.87 | TGFBR1 (0.71) | TGFBR1TGFBR2BUB1 | |
| SCHEMBL17840554 | 0.87 | TGFBR1 (0.78) | TGFBR1TGFBR2GSK3BMAPK14 | |
| SCHEMBL17840888 | 0.85 | TGFBR1 (1.00) | TGFBR1TGFBR2MAPK14 | |
| SCHEMBL17840668 | 0.84 | TGFBR1 (0.71) | TGFBR1TGFBR2BUB1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237415-A1 | TGF RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2017-11-01 | — | — | EP | claimed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | claimed |
| WO-2016106266-A1 | TGFβ RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | WO | claimed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | claimed |
| EP-3237415-A1 | TGF RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2016106266-A1 | TGFβ RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106266-A1 | TGFβ RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | TGFBR2, TGFBR1, TGFB1 | TGFBR1 2/4885TGFBR2 1/4885BUB1 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.